

Guidelines on Myocardial Revascularisation 2014 (TF13) - TF Members

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts covering the period of the Guidelines production, from Task Force creation to publication.

| Expert | Type of Relationship with Industry |
|-------------------------------|---|
| Alfonso Manterola Fernando | None declared (2011-2012-2013-2014) |
| Collet Jean-Philippe | <p>A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.</p> <ul style="list-style-type: none"> - Bristol Myers Squibb : advisory board and speaker fees (2011) - Astra Zeneca : advisory board fees (2011) - Medicines Company : consultancy (2011) - Eli Lilly : speaker fees (2011) - Sanofi Aventis : speaker fees (2011) - Abbott Vascular : speaker fees (2011) - Daiichi Sankyo : speaker fees (2011) - Astra Zeneca : antiplatelet (2012) - Eli Lilly : antiplatelet (2012) - Medco Health Solutions : antiplatelet (2012) - Accumetrics : antiplatelet agents (2012) - Bristol Myers Squibb : antiplatelet and anticoagulant (2012) - Medtronic : valves (2012) - Bristol Myers Squibb : apixaban (2013-2014) - Eli Lilly : prasugrel (2013-2014) - Bayer : rivaroxaban (2013-2014) - Daiichi Sankyo : EDOXABAN (2014) <p>D - Research funding (departmental or institutional).</p> <ul style="list-style-type: none"> - Société Française de Cardiologie : platelet function testing (2011) - Eli Lilly : prasugrel (2013) - Bristol Myers Squibb : apixaban (2013-2014) |

Guidelines on Myocardial Revascularisation 2014 (TF13) - TF Members

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts covering the period of the Guidelines production, from Task Force creation to publication.

| Expert | Type of Relationship with Industry |
|----------------------|---|
| Collet Jean-Philippe | E - Research funding (personal). <ul style="list-style-type: none"> - Accumetrics : functional platelet testing (2011) - Nanosphere : genetic testing (2011) - Eli Lilly : prasugrel (2011) - Abbott Vascular : stents (2011) |
| Cremer Jochen | A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc. <ul style="list-style-type: none"> - St. Jude Medical, Eschborn : Medical Technology and Services (2011-2012-2013-2014) - MSD Sharp & Dohme GmbH, Haar : Pharmaceutical Company (2011-2012-2013-2014) - B.Braun : Products and services for the core process in operation rooms (2011-2012-2013-2014) - Early Bird Venture Capital GmbH, Hamburg : Venture Capital (2011-2012-2013-2014) - Kelcon GmbH, Seligenstadt : Congress and Conference Management (2014) - C.T.I. GmbH, Düsseldorf : Congress and Conference Management (2014) - Cardicon GmbH, Rottach-Egern : Congress Management (2014) - congress & travel Willi Simon GmbH, Delmenhorst : Congress Management (2014) - Reiss Reisen & Events, Düsseldorf : Congress Management (2014) - m:con Mannheim congress GmbH, Mannheim : Congress Management (2014) - Doctrina Med, Wiesbaden : Medical Education (2014) - Lifebridge Medizintechnik AG, Ampfing : Medical Equipment (2014) - Astra Zeneca, Wedel : Pharmaceutical Manufacturer (2014) |
| Falk Volkmar | A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc. <ul style="list-style-type: none"> - Edwards Lifesciences : Valves (2011-2012-2013-2014) - Medtronic : valves (2011-2012-2013-2014) - Valtech : Valves (2011-2012-2013-2014) - Boston Scientific : Valves (2013-2014) |

Guidelines on Myocardial Revascularisation 2014 (TF13) - TF Members

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts covering the period of the Guidelines production, from Task Force creation to publication.

| Expert | Type of Relationship with Industry |
|----------------------|---|
| Falk Volkmar | D - Research funding (departmental or institutional). - Philips : Imaging (2011-2012-2013-2014) |
| Filippatos Gerasimos | B - Payment to your Institution: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc. - Torrent : Heart failure (2011) - Vifor International : Heart failure (2011-2012) - Bayer : Heart failure (2011-2012-2013-2014) - Corthera, Novartis : Heart failure (2011-2012-2013-2014) - Cardiorentis : Heart failure (2012-2013-2014) - Servier : Heart failure (2013-2014) D - Research funding (departmental or institutional). - Alere : Biomarkers (2012-2013-2014) E - Research funding (personal). - Nanosphere : Biomarkers (2011-2012) - European Union : Heart failure (2011-2012-2013-2014) |
| Hamm Christian | A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc. - Menarini : drugs (2011) - Boehringer Ingelheim - Ingelheim; Daiichi-Sankyo/Eli Lilly; Nycomed Pharma : drugs (2011) - Astra Zeneca, Bayer AG, Boehringer-Ingelheim, Daiichi-Sankyo, MSD, Novartis, Pfizer, Sanofi-Aventis, Servier : drugs (2011) - Cordis and Medtronic : PCI (2011) - Takeda Pharmaceuticals : drugs (2011-2012) - Daiichi Sankyo : drugs (2011-2012-2013-2014) - Pfizer : drugs (2011-2012-2013-2014) - Sanofi Aventis : drugs (2011-2012-2013-2014) - GlaxoSmithKline : drugs (2011-2012-2013-2014) - Berlin Chemie AG : drugs (2011-2012-2013-2014) |

Guidelines on Myocardial Revascularisation 2014 (TF13) - TF Members

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts covering the period of the Guidelines production, from Task Force creation to publication.

| Expert | Type of Relationship with Industry |
|----------------|--|
| Hamm Christian | <ul style="list-style-type: none"> - Heart.org : drugs (2011-2012-2013-2014) - Medicines Company : drugs (2011-2012-2013-2014) - Merck Sharp & Dohme : drugs (2011-2012-2013-2014) - BRAHMS GmbH : markers (2011-2012-2013-2014) - Siemens Healthcare : MRI (2011-2012-2013-2014) - Boston Scientific : PCI (2011-2012-2013-2014) - Duke University : study advisor (2012) - Iroko Cardio : drugs (2012-2013) - Astra Zeneca : drugs (2012-2013-2014) - Boehringer-Ingelheim : drugs (2012-2013-2014) - Novartis : drugs (2012-2013-2014) - Lilly : drugs (2012-2013-2014) - Bayer Healthcare : drugs (2012-2013-2014) - Gilead : drugs (2012-2013-2014) - Abbott Vascular : interventional devices (2012-2013-2014) - Roche Diagnostics : marker (2012-2013-2014) - Medtronic : PCI (2012-2013-2014) - TIMI group : study advisor (2012-2013-2014) - Correio : drugs (2014) <p>D - Research funding (departmental or institutional).</p> <ul style="list-style-type: none"> - Deutsche Forschungsgemeinschaft : experimental (2012-2013-2014) - German Research Foundation : experimental studies (2012-2013-2014) |
| Head Stuart | None declared (2012-2013-2014) |

Guidelines on Myocardial Revascularisation 2014 (TF13) - TF Members

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts covering the period of the Guidelines production, from Task Force creation to publication.

| Expert | Type of Relationship with Industry |
|--------------------|---|
| Juni Peter | <p>None declared (2011-2012)</p> <p>B - Payment to your Institution: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc. - see below : see below (2013)</p> <p>D - Research funding (departmental or institutional). - see below : CTU Bern is involved in design, conduct or analysis of clinical studies funded by Abbott Vascular, Ablynx, Amgen, AstraZeneca, Biosensors, Biotronik, Boehringer Ingelheim, Eisai, Eli Lilly, Exelixis, Geron, Gilead Sciences, Nestlé, Novartis, Novo Nordisc, Padma, Roche, Schering-Plough, St. Jude Medical, and Swiss Cardio Technologies. (2014)</p> |
| Kappetein A Pieter | <p>B - Payment to your Institution: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc. - Boston Scientific : TAVI (2014) - Medtronic : TAVI (2014)</p> <p>D - Research funding (departmental or institutional). - Atricure : atrial fibrillation (2011) - Boston Scientific : Coronary stenosis (2011) - Abbott Vascular : Coronary stenosis (2011) - Edwards Lifesciences : Valves (2011) - Medtronic : Valves (2011) - Abbott Vascular : Valves (2011) - Boston Scientific : stent (2012) - Medtronic : valve (2012) - Abbott Vascular : stents (2013) - Boston Scientific : TAVI (2013) - Medtronic : TAVI (2013)</p> |
| Kastrati Adnan | <p>None declared (2014)</p> <p>A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc. - Medicines Company : Anticoagulant drugs (2011-2012) - Merck Sharp & Dohme : Anticoagulant drugs (2011-2012)</p> |

Guidelines on Myocardial Revascularisation 2014 (TF13) - TF Members

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts covering the period of the Guidelines production, from Task Force creation to publication.

| Expert | Type of Relationship with Industry |
|-----------------|---|
| Kastrati Adnan | <ul style="list-style-type: none"> - Daiichi Sankyo : Antiplatelet drugs (2011-2012) - Biosensors : Stents (2011-2012) - Astra Zeneca : Antiplatelet Drugs (2012-2013) - Merck Sharp & Dohme : Anticoagulant Drugs (2013) - Biotronik : Medical Devices (2013) - Biosense : Stents (2013) <p>B - Payment to your Institution: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc. - B.Braun : Stents (2011-2012)</p> <p>D - Research funding (departmental or institutional). - Abbott Vascular : Stents (2011-2012) - Bentley Innomed : Stent (2012)</p> |
| Knuuti Juhani | <p>A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc. - Lantheus Inc : Perfusion imaging tracer development (2011-2012-2013-2014)</p> <p>D - Research funding (departmental or institutional). - Astra Zeneca : Neurology (2011) - GE Healthcare : Neurology and molecular imaging (2011) - Servier : Vascular inflammation (2012-2013-2014) - Athera : vascular inflammation (2012-2013-2014) - Orion Pharma : Heart failure drug research (2014)</p> |
| Kolh Philippe H | <p>A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc. - Merck Sharp & Dohme : Antiarrhythmic agents (2011) - Abbott Vascular : Coronary stents (2011) - Regado Biosciences : Antithrombotic agents (2011-2012) - Astra Zeneca : Antiplatelet agents (2011-2012-2013-2014) - B.Braun : Surgical instruments (2013-2014)</p> |

Guidelines on Myocardial Revascularisation 2014 (TF13) - TF Members

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts covering the period of the Guidelines production, from Task Force creation to publication.

| Expert | Type of Relationship with Industry |
|---------------------|---|
| Kolh Philippe H | <p>B - Payment to your Institution: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc. - Merck Sharp & Dohme : Antistaphylococcic vaccine (2011-2012)</p> <p>D - Research funding (departmental or institutional). - St Jude Medical : Cardiac valves (2011-2012-2013) - Boston Scientific : Coronary stents (2011-2012-2013) - Siemens Healthcare : Medical imaging (2011-2012-2013) - Johnson & Johnson : Thoracoscopic devices (2011-2012-2013) - Edwards Lifesciences : Cardiac valves (2011-2012-2013-2014) - Medtronic : Cardiac valves (2011-2012-2013-2014)</p> |
| Landmesser Ulf | <p>A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc. - Roche Pharma : Cardiovascular Research (2011-2012-2013-2014) - Sanofi Aventis : Cardiovascular Research (2012-2014) - Amgen : Cardiovascular Research (2014) - Servier : Cardiovascular Research (2014) - Berlin Chemie AG : Cardiovascular Research (2014) - Orbus Neich : Cardiovascular Research (2014)</p> <p>D - Research funding (departmental or institutional). - Pfizer : Cardiovascular Research (2014)</p> |
| Laufer Guenther | <p>D - Research funding (departmental or institutional). - Edwards Lifesciences : Valve replacement (2011-2012-2013-2014)</p> |
| Neumann Franz Josef | <p>B - Payment to your Institution: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc. - Astra Zeneca : Antiplatelet therapy (2011-2012-2013-2014) - Daiichi Sankyo : Antiplatelet therapy (2011-2012-2013-2014) - Lilly : Antiplatelet therapy (2011-2012-2013-2014) - Medicines Company : Antithrombotic therapy (2011-2012-2013-2014) - Boston Scientific : Interventional Cardiology (2011-2012-2013-2014)</p> |

Guidelines on Myocardial Revascularisation 2014 (TF13) - TF Members

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts covering the period of the Guidelines production, from Task Force creation to publication.

| Expert | Type of Relationship with Industry |
|---------------------|--|
| Neumann Franz Josef | <ul style="list-style-type: none"> - Medtronic : Interventional Cardiology (2011-2012-2013-2014) - Biotronik : Interventional Cardiology (2011-2012-2013-2014) - Boehringer-Ingelheim : Antithrombotic Therapy (2013-2014) - Edwards Lifesciences : Catheter Valves (2013-2014) D - Research funding (departmental or institutional). - Lilly : Antiplatelet therapy (2011-2012) - Medicines Company : Antithrombotic therapy (2011-2012) - Roche Pharma : Diabetes (2011-2012) - Boston Scientific : Interventional Cardiology (2011-2012) - Medtronic : Interventional Cardiology (2011-2012) - Cordis : Interventional Cardiology (2011-2012) - Braun : Interventional Cardiology (2011-2012-2013-2014) - Biotronik : Interventional Cardiology (2013-2014) - Edwards Lifesciences : Transcatheter Valves (2013-2014) |
| Richter Dimitrios | <ul style="list-style-type: none"> A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc. - Sanofi Aventis : hypertension (2011) - Pfizer : lipids (2011-2012) - Novartis : hypertension (2011-2012-2013) - Abbott : Lipids (2011-2012-2013) - Boehringer-Ingelheim : thrombosis (2011-2012-2013) - Menarini : CAD (2011-2012-2013-2014) - Unilever : lipids (2011-2012-2013-2014) - Merck Sharp & Dohme : lipids (2011-2012-2013-2014) |

Guidelines on Myocardial Revascularisation 2014 (TF13) - TF Members

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts covering the period of the Guidelines production, from Task Force creation to publication.

| Expert | Type of Relationship with Industry |
|-------------------|--|
| Richter Dimitrios | <ul style="list-style-type: none"> - Astra Zeneca : lipids-thrombosis (2011-2012-2013-2014) - Bayer Healthcare : Thrombosis (2011-2012-2013-2014) - Vianex : lipids (2012-2013-2014) - Amgen : lipids (2013-2014) - Swisspharma : lipids-hypertension (2013-2014) - Pfizer : lipids-thrombosis (2013-2014) |
| Schauerte Patrick | <p>None declared (2014)</p> <p>A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.</p> <ul style="list-style-type: none"> - Biotronik : ICDs (2011) - Impulse Dynamics : CCM (2011-2012-2013) - St Jude Medical : ICDs (2011-2012-2013) - Medtronic : ICDs, neurostimulators (2011-2012-2013) - BioControl : neurostimulators (2011-2012-2013) |
| Sousa Uva Miguel | <p>None declared (2012-2013)</p> <p>A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.</p> <ul style="list-style-type: none"> - Astra Zeneca : Ticagrelor (2011) - Astra Zeneca : Antiplatelet therapy (2014) |
| Stefanini Giulio | <p>None declared (2011-2012)</p> <p>A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.</p> <ul style="list-style-type: none"> - Biosensors : Interventional Cardiology (2013-2014) - Biotronik : Interventional Cardiology (2013-2014) - Abbott Vascular : Interventional Cardiology (2013-2014) - Astra Zeneca : Interventional Cardiology (2014) |

Guidelines on Myocardial Revascularisation 2014 (TF13) - TF Members

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts covering the period of the Guidelines production, from Task Force creation to publication.

| Expert | Type of Relationship with Industry |
|------------------|---|
| Taggart David | <p>A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.</p> <ul style="list-style-type: none"> - Abbott : speaking (2011-2012) - Medtronic Foundation : speaking (2011-2012) - Cardiovascular Research Foundation : speaking (2011-2012) - Vascular Graft Solutions : external stent for vein grafts-speaker and advisory board (2013) - Abbott : Investigator (2013-2014) - Maquet : speaker fees (2013-2014) - Vascular Graft Solutions : external stent for vein grafts-speaker and travel fees, and advisory board (2014) - medistim : speaker fees, travel for graft flow measurement (2014) <p>D - Research funding (departmental or institutional).</p> <ul style="list-style-type: none"> - Vascular Graft Solutions : pilot study (2011-2012) |
| Torracca Lucia | <p>A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.</p> <ul style="list-style-type: none"> - Sorin Group : Minimally invasive surgery (2011) - Edwards Lifesciences : valves (2011) - St Jude Medical : valves, rings, device for Afib ablation (2011) - Edwards Lifesciences : Minimally invasive surgery, valve, ring (2012-2013-2014) - Medtronic : Valve, ring (2012-2013-2014) - St Jude Medical : Valve, ring, AFib ablation device (2012-2013-2014) |
| Valgimigli Marco | <p>A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.</p> <ul style="list-style-type: none"> - Medicines Company : bivalirudin (2011) - Abbott Laboratories : ngal (2011) - Roche Pharma : PPAR alpha/gamma (2011) - CID : stent (2011-2012-2013) - Chiesi Pharma : tirofiban (2011-2012-2013) |

Guidelines on Myocardial Revascularisation 2014 (TF13) - TF Members

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts covering the period of the Guidelines production, from Task Force creation to publication.

| Expert | Type of Relationship with Industry |
|------------------|--|
| Valgimigli Marco | <ul style="list-style-type: none"> - Terumo Inc : Interventional cardiology (2011-2012-2013-2014) - Accumetrics : Platlet Function Assay (2011-2012-2013-2014) - Medtronic : stent (2011-2012-2013-2014) - Abbott Vascular : stent (2011-2012-2013-2014) - Cordis : stent (2011-2012-2013-2014) - Astra Zeneca : ticagrelor (2011-2012-2013-2014) - Iroko Cardio : Tirofiban (2011-2012-2013-2014) - Abbott Laboratories : stent (2012-2013) <p>D - Research funding (departmental or institutional).</p> <ul style="list-style-type: none"> - Abbott Laboratories : ngal (2011) |
| Wijns William | <p>B - Payment to your Institution: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.</p> <ul style="list-style-type: none"> - Eli Lilly : drug (2011) - Iroko Cardio : pharma (2011) - Biosensors : device (2011-2012-2013-2014) - Boston Scientific : device (2011-2012-2013-2014) - Edwards Lifesciences : device (2011-2012-2013-2014) - Terumo Inc : device (2011-2012-2013-2014) - Abbott Vascular : device (2011-2012-2013-2014) - Orbus Nech : device (2011-2012-2013-2014) - GlaxoSmithKline : drug (2011-2012-2013-2014) - Tryton : device (2012) - Astra Zeneca : pharma (2012) - Medtronic : device (2012-2013-2014) |

Guidelines on Myocardial Revascularisation 2014 (TF13) - TF Members

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts covering the period of the Guidelines production, from Task Force creation to publication.

| Expert | Type of Relationship with Industry |
|-------------------|--|
| Wijns William | <ul style="list-style-type: none"> - St Jude Medical : device (2012-2013-2014) - Biotronik : device (2012-2013-2014) - Cordis : device (2012-2013-2014) - MICELL : device (2012-2013-2014) - Vessix : device (2012-2013-2014) <p>D - Research funding (departmental or institutional).</p> <ul style="list-style-type: none"> - Cardio3 Biosciences : cell therapy (2011-2012-2013-2014) - Boston Scientific : device (2011-2012-2013-2014) - Medtronic : device (2011-2012-2013-2014) - St Jude Medical : device (2011-2012-2013-2014) - Biotronik : device (2011-2012-2013-2014) - Abbott Laboratories : device (2011-2012-2013-2014) - MICELL : device (2011-2012-2013-2014) - Therabel : drug (2011-2012-2013-2014) |
| Windecker Stephan | <p>A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.</p> <ul style="list-style-type: none"> - Biosensors : Stent (2011-2012) - Boston Scientific : Stent (2011-2012) - Cordis : Stent (2011-2012) - Astra Zeneca : Antiplatelet drug (2011-2012-2013) - Eli Lilly : Antiplatelet drug (2011-2012-2013) - Abbott : Stent (2011-2012-2013) - Medtronic : Stent (2011-2012-2013) - Biotronik : Stent (2011-2012-2013) |

Guidelines on Myocardial Revascularisation 2014 (TF13) - TF Members

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts covering the period of the Guidelines production, from Task Force creation to publication.

| Expert | Type of Relationship with Industry |
|-------------------|---|
| Windecker Stephan | <ul style="list-style-type: none"> - Edwards Lifesciences : TAVI (2012) D - Research funding (departmental or institutional). <ul style="list-style-type: none"> - Abbott : Stent (2011-2012) - Biosensors : Stent (2011-2012) - Medtronic : Stent (2011-2012) - Cordis : Stent (2011-2012) - St Jude Medical : OCT (2011-2012-2013-2014) - Biotronik : Stent (2011-2012-2013-2014) |
| Witkowski Adam | <ul style="list-style-type: none"> A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc. <ul style="list-style-type: none"> - Cordis : Closure devices (2011-2012-2013) - Meril Lifesciences : Stents (2011-2012-2013) - Medtronic : Corevalve aortic valve (2011-2012-2013-2014) - Medtronic : Renal denervation (2011-2012-2013-2014) - Astra Zeneca : ticagrelor (2011-2012-2013-2014) - Medicines Company : bivalirudin (2014) - Eli Lilly : prasugrel (2014) |

Guidelines on Myocardial Revascularisation 2014 (TF13) - Document Reviewers

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts covering the period of the Guidelines production, from Task Force creation to publication.

| Expert | Type of Relationship with Industry |
|-----------------------|--|
| Achenbach Stephan | <p>A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.</p> <ul style="list-style-type: none"> - Siemens Healthcare : CT (2012-2013) - Servier : Imaging (2012-2013) - Guerbet : Imaging (2012-2013) - Bayer : Anticoagulation (2013) - Behring : Anticoagulation (2013) - Astra Zeneca : Antiplatelet Therapy (2013) - Abbott : Coronary Intervention (2013) <p>D - Research funding (departmental or institutional).</p> <ul style="list-style-type: none"> - Abbott : Coronary Intervention (2013-2014) - Siemens Healthcare : Imaging (2013-2014) |
| Addad Faouzi | None declared (2012-2013-2014) |
| Aladashvili Alexander | None declared (2012-2013-2014) |
| Anelechi Anyanwu | None declared (2012-2013-2014) |
| Badimon Lina | <p>A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.</p> <ul style="list-style-type: none"> - Menarini : cardiovascular (2012) - Merck Sharp & Dohme : cardiovascular (2012) - Astra Zeneca : cardiovascular (2012-2013-2014) - Sanofi Aventis : cardiovascular (2013-2014) - GlaxoSmithKline : cardiovascular (2014) |
| Bauersachs Johann | <p>A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.</p> <ul style="list-style-type: none"> - Bayer : Afib (2012) - Actavis : CAD (2012) - Astra Zeneca : ACS (2012-2013-2014) |

Guidelines on Myocardial Revascularisation 2014 (TF13) - Document Reviewers

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts covering the period of the Guidelines production, from Task Force creation to publication.

| Expert | Type of Relationship with Industry |
|-------------------|---|
| Bauersachs Johann | <ul style="list-style-type: none"> - Daiichi Sankyo : ACS (2012-2013-2014) - Lilly : ACS (2012-2013-2014) - Boehringer-Ingelheim : Afib (2012-2013-2014) - Bristol Myers Squibb : Afib (2012-2013-2014) - Merck Sharp & Dohme : CAD, Afib (2012-2013-2014) - Pfizer : Heart Failure, Afib (2012-2013-2014) - Medtronic : Heart Failure, Hypertension (2012-2013-2014) - Berlin Chemie AG : Hypertension, CAD (2012-2013-2014) - Novartis : Hypertension, Heart Failure (2012-2013-2014) - Bayer : Afib, heart failure (2013-2014) - Orion : Heart Failure (2014) <p>D - Research funding (departmental or institutional).</p> <ul style="list-style-type: none"> - Bayer : Heart Failure (2012) - Pfizer : Heart Failure (2012) - Actavis : Heart Failure, CAD (2012-2013) - Sanofi Aventis : Heart Failure (2012-2013-2014) - Medtronic : CAD (2013-2014) - Bayer : Vascular remodeling (2013-2014) |
| Baumbach Andreas | <p>A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.</p> <ul style="list-style-type: none"> - St Jude Medical : Pressure Wire (2012) - Boston Scientific : Stents (2012-2013) - Medicines Company : Bivalirudin (2012-2013-2014) - Eli Lilly : Drugs (2012-2013-2014) |

Guidelines on Myocardial Revascularisation 2014 (TF13) - Document Reviewers

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts covering the period of the Guidelines production, from Task Force creation to publication.

| Expert | Type of Relationship with Industry |
|------------------|---|
| Baumbach Andreas | <ul style="list-style-type: none"> - Abbott Vascular : Stents (2012-2013-2014) - Keystone Heart : Embolic Deflection (2013-2014) - Stentys : Self Expanding Stent (2013-2014) <p>D - Research funding (departmental or institutional).</p> <ul style="list-style-type: none"> - Keystone Heart : Deflect (2013-2014) |
| Becker David | <p>None declared (2013)</p> <p>A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.</p> <ul style="list-style-type: none"> - Astra Zeneca : IHD (2012) - Boehringer-Ingelheim : NOAC (2012-2014) - Krka Pharma : General Cardiology (2014) - Bayer Healthcare : NOAC (2014) |
| Beygui Farzin | <p>A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.</p> <ul style="list-style-type: none"> - Astra Zeneca : Antithrombotic therapy (2012-2013-2014) - Daiichi Sankyo : Antithrombotic therapy (2012-2013-2014) - Lilly : Antithrombotic therapy (2012-2013-2014) - Servier : Coronary artery disease (2012-2013-2014) - Pfizer : Mineralocorticoid receptor blockers (2012-2013-2014) - Bristol Myers Squibb : Antithrombotic therapy (2014) - Medtronic : interventional cardiology (2014) - malinckrodt : stress testing (2014) <p>D - Research funding (departmental or institutional).</p> <ul style="list-style-type: none"> - Thermofischer : Adrenomedullin (2012-2013-2014) - Pfizer : Aldosterone (2012-2013-2014) - Astra Zeneca : Antithrombotic therapy (2012-2013-2014) |

Guidelines on Myocardial Revascularisation 2014 (TF13) - Document Reviewers

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts covering the period of the Guidelines production, from Task Force creation to publication.

| Expert | Type of Relationship with Industry |
|---------------------|--|
| Beygui Farzin | - Daiichi Sankyo : Antithrombotic therapy (2014) |
| Bonaros Nikolaos | A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc. - Medtronic : Coronary artery disease and valve therapies (2012-2013-2014) - Abbott : Mitraclip (2012-2013-2014) - Edwards Lifesciences : Transcatheter valves (2012-2013-2014) - Ziehm : Use of mobile C-arm for Transcatheter Valve implantation (2013-2014) |
| Bonnet Jean-Louis | A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc. - Abbott Vascular : Interventional Cardiology (2012-2013-2014) - Medtronic : Interventional cardiology (2012-2013-2014) - Servier : Ivabradine (2012-2013-2014) - Boston Scientific : IVUS and interventional cardiology (2012-2013-2014) - Daiichi Sankyo : Prasugrel (2012-2013-2014) - Lilly : Prasugrel (2012-2013-2014) - Bayer : Rivaroxaban (2012-2013-2014) D - Research funding (departmental or institutional). - GlaxoSmithKline : Fondaparinux (2012-2013-2014) - Lilly : PRASUGREL (2012-2013-2014) - Medtronic : STENT (2012-2013-2014) - Biotronik : STENT (2012-2013-2014) - Terumo Inc : STENT (2012-2013-2014) - Abbott Vascular : STENT (2012-2013-2014) - Astra Zeneca : TICAGRELOR (2012-2013-2014) |
| Bugiardini Raffaele | None declared (2012-2013-2014) |

Guidelines on Myocardial Revascularisation 2014 (TF13) - Document Reviewers

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts covering the period of the Guidelines production, from Task Force creation to publication.

| Expert | Type of Relationship with Industry |
|----------------------|---|
| Cequier Fillat Angel | <p>A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.</p> <ul style="list-style-type: none"> - Biosensors : Interventional Cardiology (2012) - Menarini : Medical treatment in stable patients (2012) - Astra Zeneca : Acute coronary syndromes (2012-2013-2014) - Eli Lilly : Acute coronary syndromes (2012-2013-2014) - Ferrer Internacional : Anticoagulants in PCI (2012-2013-2014) - Boston Scientific : Interventional Cardiology (2012-2013-2014) - Medtronic : Interventional Cardiology (2012-2013-2014) - Biotronik : Interventional Cardiology (2012-2013-2014) - Abbott Vascular : Interventional Cardiology (2012-2013-2014) <p>D - Research funding (departmental or institutional).</p> <ul style="list-style-type: none"> - Spanish Society of Cardiology : Antiplatelet treatments (2012-2013-2014) - Medtronic : Interventional Cardiology (2012-2013-2014) - Abbott Vascular : Interventional Cardiology (2012-2013-2014) |
| Davies John | <p>A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.</p> <ul style="list-style-type: none"> - Pfizer : Eplerenone (2012-2013-2014) - Astra Zeneca : Ticagrelor (2012-2013-2014) - Amenerini : Ranolazine (2014) <p>D - Research funding (departmental or institutional).</p> <ul style="list-style-type: none"> - Boston Scientific : Funding for research nurse (2012-2013-2014) - Zoll Medical : Therapeutic hypothermia (2012-2013-2014) |
| De Carlo Marco | <p>A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.</p> <ul style="list-style-type: none"> - Eli Lilly : acute coronary syndromes (2012) - Abbott Vascular : bioresorbable scaffolds (2014) <p>B - Payment to your Institution: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.</p> <ul style="list-style-type: none"> - The Medicines Company : bivalirudin (2013-2014) |

Guidelines on Myocardial Revascularisation 2014 (TF13) - Document Reviewers

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts covering the period of the Guidelines production, from Task Force creation to publication.

| Expert | Type of Relationship with Industry |
|------------------|--|
| Deaton M Christi | None declared (2013-2014) D - Research funding (departmental or institutional). - Novo-Nordisk : patients with heart failure and diabetes (2012) |
| Dobrev Dobromir | A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc. - Merck Sharp & Dohme : antiarrhythmic drugs (2012) - Sanofi Aventis : antiarrhythmic drugs (2013) - Daiichi-Sankyo : novel anticoagulans (2013) - Daiichi Sankyo : Honoraria (2014) - Bayer Vital : Honoraria (2014) C - Receipt of royalties for intellectual property. - Sanofi Aventis : antiarrhythmic drugs (2012) |
| Dudek Dariusz | A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc. - Nycomed : speaker fee, advisory boards, investigator. (2012) - Merck Sharp & Dohme : speaker fee, advisory boards, investigator. (2012) - Invatec AG : speaker fee, advisory boards, investigator. (2012) - Boehringer-Ingelheim : speaker fee, advisory boards, investigator. (2012-2013-2014) - Boston Scientific : speaker fee, advisory boards, investigator. (2012-2013-2014) - Eli Lilly : speaker fee, advisory boards, investigator. (2012-2013-2014) - Medtronic : speaker fee, advisory boards, investigator. (2012-2013-2014) - Pfizer : speaker fee, advisory boards, investigator. (2012-2013-2014) - Biotronik : speaker fee, advisory boards, investigator. (2012-2013-2014) - Terumo Inc : speaker fee, advisory boards, investigator. (2012-2013-2014) - Sanofi Aventis : speaker fee, advisory boards, investigator. (2012-2013-2014) - Siemens Healthcare : speaker fee, advisory boards, investigator. (2012-2013-2014) |

Guidelines on Myocardial Revascularisation 2014 (TF13) - Document Reviewers

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts covering the period of the Guidelines production, from Task Force creation to publication.

| Expert | Type of Relationship with Industry |
|---------------|--|
| Dudek Dariusz | <ul style="list-style-type: none"> - GlaxoSmithKline : speaker fee, advisory boards, investigator. (2012-2013-2014) - Bayer Healthcare : speaker fee, advisory boards, investigator. (2012-2013-2014) - Cook Medical : speaker fee, advisory boards, investigator. (2012-2013-2014) - Medicines Company : speaker fee, advisory boards, investigator. (2012-2013-2014) - Bristol Myers Squibb : speaker fee, advisory boards, investigator. (2012-2013-2014) - Balton : speaker fee, advisory boards, investigator. (2012-2013-2014) - Cordis : speaker fee, advisory boards, investigator. (2012-2013-2014) - Solvay : speaker fee, advisory boards, investigator. (2012-2013-2014) - B.Braun : speaker fee, advisory boards, investigator. (2012-2013-2014) - EuroCor : speaker fee, advisory boards, investigator. (2012-2013-2014) - Promed : speaker fee, advisory boards, investigator. (2012-2013-2014) - Tyco : speaker fee, advisory boards, investigator. (2012-2013-2014) - St Jude Medical : speaker fee, advisory boards, investigator. (2013-2014) - GE Healthcare : speaker fee, advisory boards, investigator. (2013-2014) - Bracco Pharmaceutical : speaker fee, advisory boards, investigator. (2013-2014) - Volcano : speaker fee, advisory boards, investigator. (2013-2014) - Biomatrix : speaker fee, advisory boards, investigator. (2013-2014) - Orbus Neich : speaker fee, advisory boards, investigator. (2013-2014) - MSD : speaker fee, advisory boards, investigator. (2013-2014) - InspireMD : speaker fee, advisory boards, investigator. (2013-2014) - Stentys : speaker fee, advisory boards, investigator. (2013-2014) - Abiomed : speaker fee, advisory boards, investigator. (2013-2014) |

Guidelines on Myocardial Revascularisation 2014 (TF13) - Document Reviewers

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts covering the period of the Guidelines production, from Task Force creation to publication.

| Expert | Type of Relationship with Industry |
|---------------|---|
| Dudek Dariusz | <ul style="list-style-type: none"> - Meril Life Science : speaker fee, advisory boards, investigator. (2013-2014) - Adyton Medical : speaker fee, advisory boards, investigator. (2013-2014) - Comesa Polska : speaker fee, advisory boards, investigator. (2013-2014) - Covidien Polska Sp. z o.o. : speaker fee, advisory boards, investigator. (2013-2014) - DRG MedTek : speaker fee, advisory boards, investigator. (2013-2014) - Hammermed : speaker fee, advisory boards, investigator. (2013-2014) - Iroko Cardio International : speaker fee, advisory boards, investigator. (2013-2014) - Medianet Sp. z o. o. : speaker fee, advisory boards, investigator. (2013-2014) - Possis : speaker fee, advisory boards, investigator. (2013-2014) - ProCardia Medical : speaker fee, advisory boards, investigator. (2013-2014) - REVA Medical : speaker fee, advisory boards, investigator. (2013-2014) <p>E - Research funding (personal).</p> <ul style="list-style-type: none"> - Abbott : speaker fee, advisory boards, investigator. (2012-2013-2014) - Adamed : speaker fee, advisory boards, investigator. (2012-2013-2014) - Astra Zeneca : speaker fee, advisory boards, investigator. (2012-2013-2014) - Boehringer-Ingelheim : speaker fee, advisory boards, investigator. (2012-2013-2014) - Boston Scientific : speaker fee, advisory boards, investigator. (2012-2013-2014) - Eli Lilly : speaker fee, advisory boards, investigator. (2012-2013-2014) - Medtronic : speaker fee, advisory boards, investigator. (2012-2013-2014) - Pfizer : speaker fee, advisory boards, investigator. (2012-2013-2014) - Biotronik : speaker fee, advisory boards, investigator. (2012-2013-2014) - Terumo Inc : speaker fee, advisory boards, investigator. (2012-2013-2014) - Sanofi Aventis : speaker fee, advisory boards, investigator. (2012-2013-2014) |

Guidelines on Myocardial Revascularisation 2014 (TF13) - Document Reviewers

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts covering the period of the Guidelines production, from Task Force creation to publication.

| Expert | Type of Relationship with Industry |
|---------------|---|
| Dudek Dariusz | <ul style="list-style-type: none"> - Siemens Healthcare : speaker fee, advisory boards, investigator. (2012-2013-2014) - GlaxoSmithKline : speaker fee, advisory boards, investigator. (2012-2013-2014) - Bayer Healthcare : speaker fee, advisory boards, investigator. (2012-2013-2014) - Cook Medical : speaker fee, advisory boards, investigator. (2012-2013-2014) - Medicines Company : speaker fee, advisory boards, investigator. (2012-2013-2014) - Nycomed : speaker fee, advisory boards, investigator. (2012-2013-2014) - Balton : speaker fee, advisory boards, investigator. (2012-2013-2014) - Merck Sharp & Dohme : speaker fee, advisory boards, investigator. (2012-2013-2014) - Cordis : speaker fee, advisory boards, investigator. (2012-2013-2014) - Solvay : speaker fee, advisory boards, investigator. (2012-2013-2014) - B.Braun : speaker fee, advisory boards, investigator. (2012-2013-2014) - EuroCor : speaker fee, advisory boards, investigator. (2012-2013-2014) - Invatec AG : speaker fee, advisory boards, investigator. (2012-2013-2014) - Promed : speaker fee, advisory boards, investigator. (2012-2013-2014) - Tyco : speaker fee, advisory boards, investigator. (2012-2013-2014) - Biomatrix : speaker fee, advisory boards, investigator. (2012-2013-2014) - InspireMD : speaker fee, advisory boards, investigator. (2012-2013-2014) |
| Dunning Joel | <p>None declared (2014)</p> <p>A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.</p> <ul style="list-style-type: none"> - Maquet : Intraortic balloon counterpulsation (2012-2013) |
| Eeckhout Eric | <p>B - Payment to your Institution: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.</p> <ul style="list-style-type: none"> - Abbott Vascular : speakers fee (2012-2013) - St Jude Medical : PROCTORING (2012-2013-2014) |

Guidelines on Myocardial Revascularisation 2014 (TF13) - Document Reviewers

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts covering the period of the Guidelines production, from Task Force creation to publication.

| Expert | Type of Relationship with Industry |
|-------------------|---|
| Eeckhout Eric | <ul style="list-style-type: none"> - Abbott Vascular : speakers fee PI of study (2014) D - Research funding (departmental or institutional). <ul style="list-style-type: none"> - Biosensors : research funding (2012-2013-2014) - Boston Scientific : research funding (2012-2013-2014) - Biotronik : research funding (2013-2014) - stentsys : research funding (2013-2014) |
| Eha Jaan | <ul style="list-style-type: none"> A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc. <ul style="list-style-type: none"> - Menarini : lectures AH (2012) - Astra Zeneca : lectures stable CAD (2012) - Novartis : aliskiren (2012-2013-2014) - Servier : Ivabradine (2012-2013-2014) - Menarini : lectures, AH (2013-2014) - Astra Zeneca : lectures, stable CAD (2013-2014) |
| Erlinge David | <ul style="list-style-type: none"> A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc. <ul style="list-style-type: none"> - Astra Zeneca : Antithrombotic (2012-2013-2014) - Boehringer-Ingelheim : Antithrombotic (2012-2013-2014) - Lilly : Antithrombotic (2012-2013-2014) D - Research funding (departmental or institutional). <ul style="list-style-type: none"> - Lilly : Antithrombotic (2012-2013-2014) |
| Felice Herbert | None declared (2012-2013-2014) |
| Georgiou Georgios | None declared (2012-2013-2014) |
| Gielen Stephan | <ul style="list-style-type: none"> A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc. <ul style="list-style-type: none"> - Astra Zeneca : Lectures 2012 (2012) - Astra Zeneca : Lectures 2013 (2013-2014) - Bayer Healthcare : Lectures 2013 (2013-2014) |

Guidelines on Myocardial Revascularisation 2014 (TF13) - Document Reviewers

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts covering the period of the Guidelines production, from Task Force creation to publication.

| Expert | Type of Relationship with Industry |
|--------------------|---|
| Gielen Stephan | <ul style="list-style-type: none"> - Novartis : Lectures 2013-14, Travel grant AHA (2013-2014) - Servier : Chairman, Satellite Symposium 2014 EuroPREvent (2014) |
| Gudnason Thorarinn | <p>A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.</p> <ul style="list-style-type: none"> - Astra Zeneca : Brilique (2012) - Novartis : Heart failure (2014) <p>B - Payment to your Institution: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.</p> <ul style="list-style-type: none"> - Novartis : Heart failure (2012) <p>E - Research funding (personal).</p> <ul style="list-style-type: none"> - Novartis : Heart failure (2013) |
| Hambrecht Rainer | <p>A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.</p> <ul style="list-style-type: none"> - Lilly : prasugrel (2012-2013-2014) - Berlin Chemie AG : ranolazin (2012-2013-2014) - Astra Zeneca : ticagrelor (2012-2013-2014) - Merck Sharp & Dohme : tredaptive (2012-2013-2014) <p>B - Payment to your Institution: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.</p> <ul style="list-style-type: none"> - Medicines Company : Bivalirudin (2012) <p>C - Receipt of royalties for intellectual property.</p> <ul style="list-style-type: none"> - Medicines Company : Bivalirudin (2012) <p>D - Research funding (departmental or institutional).</p> <ul style="list-style-type: none"> - Iroko Cardio : aggrastat (2012) - Medicines Company : Bivalirudin (2013-2014) |
| Hasdai David | <p>A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.</p> <ul style="list-style-type: none"> - Boehringer-Ingelheim : Pradaxa (2012-2013-2014) - Bayer : Rivaroxiban (2012-2013-2014) - Astra Zeneca : Ticagrelor (2012-2013-2014) |
| Hudec Martin | <p>A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.</p> <ul style="list-style-type: none"> - Servier : Ivabradin (2012-2013) |

Guidelines on Myocardial Revascularisation 2014 (TF13) - Document Reviewers

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts covering the period of the Guidelines production, from Task Force creation to publication.

| Expert | Type of Relationship with Industry |
|--------------------|---|
| Hudec Martin | <ul style="list-style-type: none"> - Lilly : Prasugrel (2012-2013) - Pfizer : Atorvastatin, Eplerenon (2012-2013-2014) - Merck Sharp & Dohme : Bisoprolol (2012-2013-2014) - Astra Zeneca : Ticagrelor (2014) <p>E - Research funding (personal).</p> <ul style="list-style-type: none"> - Sanofi Aventis : Otamixaban (2012-2013) |
| Ibrahimov Firdovsi | None declared (2012-2013-2014) |
| Junker Anders Bo | <p>A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.</p> <ul style="list-style-type: none"> - Lilly : prasugrel (2012-2013-2014) - Astra Zeneca : Ticagrelor (2012-2013-2014) |
| Kedev Sasko | <p>A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.</p> <ul style="list-style-type: none"> - Abbott Vascular : Speaker fees (2012-2013) - Boston Scientific : Speaker fees (2013-2014) - Medtronic : Speaker fees (2014) <p>C - Receipt of royalties for intellectual property.</p> <ul style="list-style-type: none"> - Medtronic : Honoraria (2012-2013) |
| Kirchhof Paulus | <p>A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.</p> <ul style="list-style-type: none"> - Boehringer-Ingelheim : cardiovascular (2012-2013-2014) - Daiichi Sankyo : cardiovascular (2012-2013-2014) - Medtronic : cardiovascular (2012-2013-2014) - Pfizer : cardiovascular (2012-2013-2014) - St Jude Medical : cardiovascular (2012-2013-2014) - Sanofi Aventis : cardiovascular (2012-2013-2014) - Meda pharma : cardiovascular (2012-2013-2014) - Bristol Myers Squibb : cardiovascular (2012-2013-2014) |

Guidelines on Myocardial Revascularisation 2014 (TF13) - Document Reviewers

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts covering the period of the Guidelines production, from Task Force creation to publication.

| Expert | Type of Relationship with Industry |
|-----------------|--|
| Kirchhof Paulus | <ul style="list-style-type: none"> - Merck Sharp & Dohme : cardiovascular (2012-2013-2014) - Otsuka Pharmaceuticals Development and Commercialization (consultancy) : cardiovascular (2012-2013-2014) - Johnson & Johnson : cardiovascular (2014) - Bayer Healthcare : cardiovascular (2014) <p>B - Payment to your Institution: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.</p> <ul style="list-style-type: none"> - Portola Pharmaceuticals : cardiovascular (2012) - Boehringer-Ingelheim : cardiovascular (2012-2013-2014) - Bayer Healthcare : cardiovascular (2012-2013-2014) - BMS / Pfizer alliance : cardiovascular (2012-2013-2014) - Gilead : cardiovascular (2013) - Daiichi Sankyo : cardiovascular (2014) <p>D - Research funding (departmental or institutional).</p> <ul style="list-style-type: none"> - St Jude Medical : cardiovascular (2012-2013) - Sanofi Aventis : cardiovascular (2012-2013) - Meda pharma : cardiovascular (2012-2013-2014) - British Heart Foundation : cardiovascular (2014) - European Union (FP7) : cardiovascular (2014) - Daiichi Sankyo : cardiovascular (IIT grant to AFNET) (2014) - St Jude Medical : cardiovascular (IIT grant to AFNET) (2014) - Sanofi Aventis : cardiovascular (IIT grant to AFNET) (2014) - BMS/Pfizer : cardiovascular (IIT grant to AFNET) (2014) - Fondation Leducq : cardiovascular (starting in October 2014) (2014) - German Ministry of Education and Research (BMBF) : cardiovascular (to AFNET) (2014) |

Guidelines on Myocardial Revascularisation 2014 (TF13) - Document Reviewers

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts covering the period of the Guidelines production, from Task Force creation to publication.

| Expert | Type of Relationship with Industry |
|--------------------|--|
| Legrand Victor M | <p>A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.</p> <ul style="list-style-type: none"> - Astra Zeneca : advisory board fees (2012) - Medtronic : Core valve proctoring and advisory board fees (2012) - Astra Zeneca : antiplatelet (2013) - Medtronic : device (2014) - Astra Zeneca : pharmaceutical (2014) <p>B - Payment to your Institution: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.</p> <ul style="list-style-type: none"> - Medtronic : TAVI (2013) |
| Luckraz Heyman | None declared (2012-2013-2014) |
| Mahrholdt Heiko | <p>A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.</p> <ul style="list-style-type: none"> - Institut für Herzinfarktforschung Ludwigshafen, Germany : Consultant (2012-2013-2014) <p>D - Research funding (departmental or institutional).</p> <ul style="list-style-type: none"> - Robert Bosch Foundation : Research Grants (2012-2013-2014) |
| Mirrakhimov Aibek | None declared (2012-2013-2014) |
| Montalescot Gilles | <p>A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.</p> <ul style="list-style-type: none"> - GlaxoSmithKline : Cardiology (2012) - Bristol Myers Squibb : Cardiology (2012) - Astra Zeneca : Cardiology (2012-2013) - Eli Lilly : Cardiology (2012-2013) - Medtronic : Cardiology (2012-2013) - Novartis : Cardiology (2012-2013) - Biotronik : Cardiology (2012-2013) - Sanofi Aventis : Cardiology (2012-2013) - Menarini : Cardiology (2012-2013) - Roche Pharma : Cardiology (2012-2013) |

Guidelines on Myocardial Revascularisation 2014 (TF13) - Document Reviewers

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts covering the period of the Guidelines production, from Task Force creation to publication.

| Expert | Type of Relationship with Industry |
|--------------------|--|
| Montalescot Gilles | <ul style="list-style-type: none"> - Duke Institute : Cardiology (2012-2013) - Iroko Cardio : Cardiology (2012-2013) - The Medicines Company : Cardiology (2012-2013) - Springer : Cardiology (2012-2013) - Wolters : Cardiology (2012-2013) - Bayer : Cardiology (2012-2013-2014) - Boehringer-Ingelheim : Cardiology (2012-2013-2014) - WebMD : Cardiology (2012-2013-2014) - TIMI group : Cardiology (2012-2013-2014) - Europa : Cardiology (2012-2013-2014) - Lead-Up : Cardiology (2012-2013-2014) - Pfizer : Cardiology (2013) - Accumetrics : Cardiology (2013) - BMS : Cardiology (2013) - GSK : Cardiology (2013) - Servier : Cardiology (2014) - GLG : Cardiology (2014) - McKinsey : Cardiology (2014) - Iroko Cardio International : Cardiology (2014) - CFR : Cardiology (2014) - LLC : Cardiology (2014) - Luminex : Cardiology (2014) |

Guidelines on Myocardial Revascularisation 2014 (TF13) - Document Reviewers

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts covering the period of the Guidelines production, from Task Force creation to publication.

| Expert | Type of Relationship with Industry |
|--------------------|--|
| Montalescot Gilles | <ul style="list-style-type: none"> - Remedica : Cardiology (2014) B - Payment to your Institution: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc. - Astra Zeneca : Cardiology (2012) - Daiichi Sankyo : Cardiology (2012) - Biotronik : Cardiology (2012) - Sanofi Aventis : Cardiology (2012) - Roche Pharma : Cardiology (2012) - Abbott Vascular : Cardiology (2012) - Fédération Française de Cardiologie : Cardiology (2012) - Fondation de France : Cardiology (2012) - INSERM : Cardiology (2012) - Société Française de Cardiologie : Cardiology (2012) - Institut de France : Cardiology (2012) - Nanospheres : Cardiology (2012) - Stentys : Cardiology (2012) - Eli Lilly : Cardiology (2012-2014) - Medtronic : Cardiology (2012-2014) - Pfizer : Cardiology (2012-2014) - Menarini : Cardiology (2012-2014) - Bristol Myers Squibb : Cardiology (2012-2014) - The Medicines Company : Cardiology (2012-2014) - Accumetrics : Cardiology (2014) - Sanofi-Aventis : Cardiology (2014) |

Guidelines on Myocardial Revascularisation 2014 (TF13) - Document Reviewers

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts covering the period of the Guidelines production, from Task Force creation to publication.

| Expert | Type of Relationship with Industry |
|--------------------|---|
| Montalescot Gilles | <ul style="list-style-type: none"> - Astrazeneca : Cardiology (2014) - Biotronik : Cardiology (2014) D - Research funding (departmental or institutional). <ul style="list-style-type: none"> - Astra Zeneca : Cardiology (2013) - Eli Lilly : Cardiology (2013) - Medtronic : Cardiology (2013) - Pfizer : Cardiology (2013) - Biotronik : Cardiology (2013) - Sanofi Aventis : Cardiology (2013) - Menarini : Cardiology (2013) - Nanosphere : Cardiology (2013) - Roche Pharma : Cardiology (2013) - Fédération Française de Cardiologie : Cardiology (2013) - Fondation de France : Cardiology (2013) - INSERM : Cardiology (2013) - Société Française de Cardiologie : Cardiology (2013) - Accumetrics : Cardiology (2013) - The Medicines Company : Cardiology (2013) - Institut de France : Cardiology (2013) - Stentys : Cardiology (2013) - BMS : Cardiology (2013) - Daiichi Sankyo : Cardiology (2013-2014) - Abbott Vascular : Cardiology (2013-2014) |

Guidelines on Myocardial Revascularisation 2014 (TF13) - Document Reviewers

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts covering the period of the Guidelines production, from Task Force creation to publication.

| Expert | Type of Relationship with Industry |
|--------------------|---|
| Nedeljkovic Milan | None declared (2012-2013-2014) |
| Paparella Domenico | None declared (2012-2013) D - Research funding (departmental or institutional). - Edwards Lifesciences : heart valve prosthesis (2014) |
| Pepper John | None declared (2012-2013-2014) |
| Pereira Helder | None declared (2013) A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc. - Abbott : Advisory board (2012) - Boston Scientific : Advisory board (2012) - Lilly : Speakeasy fee (2012) - Pfizer : Speaker fee (2012) B - Payment to your Institution: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc. - AstraZenaca : platelet antiaggregation (2014) |
| Pereira Bruno | None declared (2013) A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc. - Abbott : Speaker Fees (2012) - Astra Zeneca : Speaker Fees (2012-2014) - Abbott Vascular : Speaker Fees (2014) |
| Postadzhiyan Arman | A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc. - Astra Zeneca : ACS (2012-2013-2014) - Boehringer-Ingelheim : AF (2012-2013-2014) |
| Rastan Ardawan | B - Payment to your Institution: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc. - JenaValve Technology : transcatheter aortic valve implantation (2012-2013-2014) D - Research funding (departmental or institutional). - Siemens Healthcare : Transcatheter aortic valve implantation (2012-2013-2014) |
| Roffi Marco | A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc. - Daiichi Sankyo : antiplatelet therapy (2012-2013) |

Guidelines on Myocardial Revascularisation 2014 (TF13) - Document Reviewers

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts covering the period of the Guidelines production, from Task Force creation to publication.

| Expert | Type of Relationship with Industry |
|-----------------------------|--|
| Roffi Marco | <ul style="list-style-type: none"> - Lilly : antiplatelet therapy (2012-2013) - Astra Zeneca : antiplatelet therapy (2012-2013) D - Research funding (departmental or institutional). <ul style="list-style-type: none"> - Biosensors : devices (2012-2013-2014) - Boston Scientific : devices (2012-2013-2014) - Medtronic : devices (2012-2013-2014) - Biotronik : devices (2012-2013-2014) - Abbott Vascular : devices (2012-2013-2014) |
| Romppanen Hannu | None declared (2012-2013-2014) |
| Sakhov Orazbek | A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc. <ul style="list-style-type: none"> - Medtronic : Central and Eastern Europe Coronary Advisory Board member (2012) - Medtronic : Central and Eastern Europe Coronary Advisory Board member; Lectures in Academia Medtronic (2013-2014) |
| Sanmartin Fernandez Marcelo | A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc. <ul style="list-style-type: none"> - Boehringer-Ingelheim : Atrial Fibrillation (2012) - Servier : Heart Failure (2012) - Daiichi Sankyo : Hypertension (2012) - Novartis : Hypertension (2012) - Bayer Healthcare : Atrial fibrillation (2012-2014) - Lilly : Acute Coronary Syndromes (2013) - Bristol Myers Squibb : Atrial Fibrillation (2013) - Ferrer Spain : Hypercholesterolemia (2013) - Astra Zeneca : Acute Coronary Syndromes (2013-2014) - Pfizer : Atrial Fibrillation (2014) |

Guidelines on Myocardial Revascularisation 2014 (TF13) - Document Reviewers

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts covering the period of the Guidelines production, from Task Force creation to publication.

| Expert | Type of Relationship with Industry |
|-----------------------------|---|
| Sanmartin Fernandez Marcelo | B - Payment to your Institution: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc. - Astra Zeneca : Acute Coronary Syndromes (2013-2014) |
| Segev Amit | A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc. - Astra Zeneca : cardiology (2012) - Eli Lilly : cardiology (2012) - Bayer Schering Pharma : cardiology (2012) - Edwards Lifesciences : Interventional cardiology (2012) - Medtronic : Interventional cardiology (2012) - Pfizer : Cardiology (2012-2013) - Boston Scientific : Interventional cardiology (2012-2013) - Abbott Vascular : Interventional Cardiology (2013) - Edwards Lifesciences : Interventional Cardiology, TAVI proctor (2013) - Medtronic : Interventional Cardiology, TAVI proctor (2013) - Edwards Lifesciences : TAVI - proctor (2014) - Medtronic : TAVI - proctor (2014) |
| Sergeant Paul | B - Payment to your Institution: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc. - Johnson & Johnson : educational courses (2012) - Medtronic Foundation : educational courses (2012) - Ethicon Endo Surgery GmbH : education simulation (2013) - Medtronic Foundation : OPCAB education (2013) - Medtronic : education (2014) - Ethicon Endo Surgery GmbH : education (2014) |
| Silber Sigmund | B - Payment to your Institution: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc. - Orbus Neich : EPC stent, Clinical Registry (2012) |

Guidelines on Myocardial Revascularisation 2014 (TF13) - Document Reviewers

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts covering the period of the Guidelines production, from Task Force creation to publication.

| Expert | Type of Relationship with Industry |
|-------------------|--|
| Silber Sigmund | <ul style="list-style-type: none"> - Astra Zeneca : Ticagrelor, speaker fees (2012) - Boston Scientific : Drug-eluting stents, Platinum Plus Trial (2012-2013) - Medtronic : Drug-eluting stents, Resolute AC Trial (2012-2013-2014) - Daiichi Sankyo : Prasugrel, speaker fees (2012-2013-2014) - Lilly : Prasugrel, speaker fees (2014) <p>D - Research funding (departmental or institutional).</p> <ul style="list-style-type: none"> - Celonova : COBRA Trial (2012-2013-2014) - MSD : REVEAL Trial (2013-2014) |
| Skoric Bosko | <p>A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.</p> <ul style="list-style-type: none"> - Berlin Chemie AG : Nebilet (2012) - Abbott : Omacor (2012) - Astra Zeneca : ticagrelor (2012) - Abbott : Prograf (2013) - Astra Zeneca : Ranexa (2013) - Berlin Chemie AG : Ranexa (2013-2014) - Servier : Corlentor (2014) - Astellas : Prograf (2014) <p>D - Research funding (departmental or institutional).</p> <ul style="list-style-type: none"> - Ministry of Science, Education and Sport of the Republic of Croatia : platelet function testing (2012-2013-2014) |
| Tamargo Juan Luis | <p>A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.</p> <ul style="list-style-type: none"> - sanodi-aventis : Dronedarone-antiarrhythmic agent (2012) - Menarini : Ranolazina (2013) - Menarini : Ranolazine (2014) <p>B - Payment to your Institution: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.</p> <ul style="list-style-type: none"> - Astra Zeneca (Unrestricted Grant) : Candesartan, Felodipine, Atenolol (2014) |

Guidelines on Myocardial Revascularisation 2014 (TF13) - Document Reviewers

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts covering the period of the Guidelines production, from Task Force creation to publication.

| Expert | Type of Relationship with Industry |
|--------------------|---|
| Tamargo Juan Luis | <p>D - Research funding (departmental or institutional). - Astra Zeneca : Unrestricted Grant (2013)</p> <p>E - Research funding (personal). - Astra -Zeneca Foundation (NON-PROFIT FOUNDATION). two years Unrestricted Grant : None (2012) - Instituto de Salud Carlos III. Ministerio de Economía y Competitividad. Gobierno de España : No product/device (2014)</p> |
| Ten Berg Jurrien M | <p>A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc. - Astra Zeneca : advisory board (2012-2013-2014) - Medicines Company : advisory board fee (2012-2013-2014) - Merck Sharp & Dohme : advisory board fees (2012-2013-2014) - Eli Lilly : speaker fee (2012-2013-2014)</p> |
| Terzic Ibrahim | None declared (2012-2013-2014) |
| Thiele Holger | <p>A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc. - Boehringer-Ingelheim : Anticoagulation (2012) - Medicines Company : Anticoagulation (2012) - Astra Zeneca : Antithrombotics (2012) - Eli Lilly : Antithrombotics (2012) - Boehringer Ingelheim : Anticoagulation (2013-2014) - Astra Zeneca : Antiplatelets (2013-2014) - Daiichi Sankyo : Antiplatelets (2013-2014) - Lilly : Antiplatelets (2013-2014)</p> <p>D - Research funding (departmental or institutional). - Medicines Company : anticoagulation (2012) - Eli Lilly : Antithrombotics (2012) - Maquet : Assist Device (2012) - Teleflex Medical : Assist Device (2012)</p> |

Guidelines on Myocardial Revascularisation 2014 (TF13) - Document Reviewers

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts covering the period of the Guidelines production, from Task Force creation to publication.

| Expert | Type of Relationship with Industry |
|----------------------------------|--|
| Thiele Holger | <ul style="list-style-type: none"> - Terumo Inc : thrombectomy (2012-2013-2014) - Lilly : Antiplatelets (2013-2014) |
| Trovik Thor | <p>None declared (2014)</p> <p>A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.</p> <ul style="list-style-type: none"> - Biosensors : Coronary stents (Advisory Board Fee) (2012) - Astra Zeneca : Cardiological drugs - Advisory Board fee (2013) |
| van Geuns Robert-Jan Matthijs | <p>B - Payment to your Institution: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.</p> <ul style="list-style-type: none"> - Abbott Vascular : Medical Devices (2012-2013-2014) - Stentys SAS : Medical Devices (2012-2013-2014) - Tryton Inc : Medical Devices (2012-2013-2014) - Boston Scientific : Medical Devices (2014) <p>D - Research funding (departmental or institutional).</p> <ul style="list-style-type: none"> - Abbott Vascular : Medical Devices (2012-2013-2014) - Tryton Inc : Medical Devices (2012-2013-2014) - Boston Scientific : Medical Devices (2014) |
| Wagner Hans-Otto | <p>A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.</p> <ul style="list-style-type: none"> - Pfizer : New oral anticoagulants (2012-2013-2014) |
| Wassmann Sven | <p>A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.</p> <ul style="list-style-type: none"> - Biosensors : Cardiovascular (2012) - Medtronic : Cardiovascular (2012) - Boehringer-Ingelheim : Cardiovascular (2012-2013-2014) - Novartis : Cardiovascular (2012-2013-2014) - Pfizer : Cardiovascular (2012-2013-2014) - Merck Sharp & Dohme : Cardiovascular (2012-2013-2014) - Astra Zeneca : Cardiovascular (2012-2014) |

Guidelines on Myocardial Revascularisation 2014 (TF13) - Document Reviewers

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts covering the period of the Guidelines production, from Task Force creation to publication.

| Expert | Type of Relationship with Industry |
|-----------------|--|
| Wassmann Sven | <ul style="list-style-type: none"> - Lilly : Cardiovascular (2012-2014) - Bayer Healthcare : Cardiovascular (2013-2014) - Bristol Myers Squibb : Cardiovascular (2013-2014) - Abbott Vascular : Cardiovascular (2014) - UCB : Cardiovascular (2014) <p>B - Payment to your Institution: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.</p> <ul style="list-style-type: none"> - Biosensors : Cardiovascular (2014) - Terumo Inc : Cardiovascular (2014) - Nicolai : Cardiovascular (2014) |
| Weidinger Franz | <p>A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.</p> <ul style="list-style-type: none"> - Abbott : DES (2012) - Servier : Ivabradin (2012) - Daiichi Sankyo : Prasugrel (2012) - Astra Zeneca : Ticagrelor (2012) - Bayer Healthcare : Rivaroxaban (2012-2013) - Pfizer : Apixaban (2012-2013-2014) - Biotronik : Stents (2012-2013-2014) - Daiichi Sankyo : Edoxaban (2013-2014) - Lilly : Prasugrel (2013-2014) - Astra Zeneca : Ticagrelor, Saxagliptin (2013-2014) <p>B - Payment to your Institution: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.</p> <ul style="list-style-type: none"> - Astra Zeneca : Antiplatelet therapy (2012) - Daiichi Sankyo : Antiplatelet therapy (2012-2013) - Merck Sharp & Dohme : Lipid lowering (2012-2013-2014) |

Guidelines on Myocardial Revascularisation 2014 (TF13) - Document Reviewers

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts covering the period of the Guidelines production, from Task Force creation to publication.

| Expert | Type of Relationship with Industry |
|--------------------------|---|
| Weidinger Franz | <ul style="list-style-type: none"> - Biotronik : Drug-eluting stent (2014) - Sanofi Aventis : Lipid lowering (2014) - Bayer Healthcare : Rivaroxaban (2014) |
| Wendler Olaf | <p>A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.</p> <ul style="list-style-type: none"> - Edwards Lifesciences : Heart valves (2012) - Medtronic : Transcatheter heart valves (2012) - Apica : Left ventricular closure device (2012-2013-2014) - St Jude Medical : Transcatheter heart valves (2012-2013-2014) - JenaValve Technology : Transcatheter heart valves (2012-2013-2014) - Bioventrix : Left Ventricular Reduction Device (2013-2014) - Cardiosolutions : Mitral Valve Repair Devce (2013-2014) - Edwards Lifesciences : Transcatheter Heart valves (2013-2014) <p>D - Research funding (departmental or institutional).</p> <ul style="list-style-type: none"> - Edwards Lifesciences : Transcatheter Heart Valves (2013-2014) |
| Yildirim Aylin | <p>B - Payment to your Institution: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.</p> <ul style="list-style-type: none"> - Merck Sharp & Dohme : investigator in a multicenter study (Improve it) (2012-2013) - Astra Zeneca : Speaker fee (2014) |
| Zamorano Gomez Jose Luis | <p>A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.</p> <ul style="list-style-type: none"> - Abbott Vascular : Help in Design Echocardiographic protocol (2012) - Merck Sharp & Dohme : Lecture (2012) - Daiichii : Atrial Fib (2013) - Merck Sharp & Dohme : Lipid Lowering (2013) - Philips : 3D echo (2014) - MSD : CV risk factors (2014) |

Guidelines on Myocardial Revascularisation 2014 (TF13) - Document Reviewers

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts covering the period of the Guidelines production, from Task Force creation to publication.

| Expert | Type of Relationship with Industry |
|--------------------------|---|
| Zamorano Gomez Jose Luis | <ul style="list-style-type: none"> - Toshiba medical imaging : fusion imaging 3D echo CT (2014) B - Payment to your Institution: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc. <ul style="list-style-type: none"> - European Research Foundation FP7 : CV Imaging (2012) - European Research FP7 : CV Imaging (2013) - Servier : Imaging in ISchemic patients (2013) - Siemens Healthcare : 3d echo software and free style echo (2014) C - Receipt of royalties for intellectual property. <ul style="list-style-type: none"> - Springer : ESC Textbook of CV Imaging (2012-2013) D - Research funding (departmental or institutional). <ul style="list-style-type: none"> - Astra Zeneca : Clinical trial (2014) - Icaria : Clinical trial (2014) |
| Zelizko Michael | None declared (2012-2013-2014) |

Committee for Practice Guidelines 2012-2014

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts covering the period of the Guidelines production, from Task Force creation to publication.

| Expert | Type of Relationship with Industry |
|--------------------|---|
| Achenbach Stephan | <p>A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.</p> <ul style="list-style-type: none"> - Siemens Healthcare : CT (2012-2013) - Servier : Imaging (2012-2013) - Guerbet : Imaging (2012-2013) - Bayer : Anticoagulation (2013) - Behring : Anticoagulation (2013) - Astra Zeneca : Antiplatelet Therapy (2013) - Abbott : Coronary Intervention (2013) <p>D - Research funding (departmental or institutional).</p> <ul style="list-style-type: none"> - Abbott : Coronary Intervention (2013-2014) - Siemens Healthcare : Imaging (2013-2014) |
| Baumgartner Helmut | <p>A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.</p> <ul style="list-style-type: none"> - Actelion : Bosentan for PAH treatment in congenital heart disease (2012) - Edwards Lifesciences : transcatheter valve implantation (2012-2013-2014) - Actelion : Bosentan and Macicentan for PAH treatment in congenital heart disease (2013-2014) - St. Jude Medical : Occluders for shunt closure (ASD, PFO, PDA, VSD) (2013-2014) - Abbott : transcather mitral valve repair (Mitraclip) (2013-2014) - Direct Flow Medical : transcatheter valve implantation (2013-2014) <p>B - Payment to your Institution: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.</p> <ul style="list-style-type: none"> - Actelion : Bosentan for PAH treatment in congenital heart disease (2012-2013-2014) - Edwards Lifesciences : transcatheter valve implantation (2012-2013-2014) - St. Jude Medical : Occluders for shunt closure (ASD, PFO, PDA, VSD) (2013-2014) - Abbott : transcather mitral valve repair (Mitraclip) (2013-2014) - Direct Flow Medical : transcatheter valve implantation (2013-2014) |

Committee for Practice Guidelines 2012-2014

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts covering the period of the Guidelines production, from Task Force creation to publication.

| Expert | Type of Relationship with Industry |
|--------------|---|
| Bax Jeroen | <p>D - Research funding (departmental or institutional).</p> <ul style="list-style-type: none"> - Servier : Farma (2012-2013-2014) - Edwards Lifesciences : Heart Valves (2012-2013-2014) - GE Healthcare : Imaging (2012-2013-2014) - Lantheus Inc : Imaging (2012-2013-2014) - Boston Scientific : Pacing (2012-2013-2014) - Medtronic : Pacing (2012-2013-2014) - St Jude Medical : Pacing (2012-2013-2014) - Biotronik : Pacing (2012-2013-2014) |
| Bueno Hector | <p>A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.</p> <ul style="list-style-type: none"> - Novartis : Heart Failure and elinogrel (2012) - Bayer Healthcare : Aspirin, rivaroxaban (2012-2013-2014) - Roche Pharma : Dalcetrapib (2012-2013-2014) - Daiichi Sankyo : Prasugrel (2012-2013-2014) - Eli Lilly : Prasugrel (2012-2013-2014) - Astra Zeneca : Ticagrelor (2012-2013-2014) - BMS/Pfizer : Apixaban (2013) - Novartis : Relaxin (2013) - Sanofi Aventis : Clopidogrel (2013-2014) - Pfizer : Apixaban (2014) - Bristol Myers Squibb : Apixaban (2014) - Menarini : Ranolazine (2014) - Novartis : Serelaxin (2014) |

Committee for Practice Guidelines 2012-2014

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts covering the period of the Guidelines production, from Task Force creation to publication.

| Expert | Type of Relationship with Industry |
|------------------|--|
| Bueno Hector | E - Research funding (personal). - Astra Zeneca : Ticagrelor (2012-2013-2014) |
| Deaton M Christi | None declared (2013-2014) D - Research funding (departmental or institutional). - Novo-Nordisk : patients with heart failure and diabetes (2012) |
| Erol Cetin | A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc. - Servier : Hypertension (2013-2014) B - Payment to your Institution: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc. - Servier : Perindopril (2012) - Menarini : Trandolapril (2012) - Menarini : Hypertension (2013-2014) C - Receipt of royalties for intellectual property. - Astra Zeneca : Ticagrelor (2012) |
| Fagard Robert | None declared (2012-2013-2014) |
| Ferrari Roberto | A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc. - Boehringer-Ingelheim : Anticoagulant and diabetes. Dagabitran (2012) - Medical Trials Analysis : Consultant in Clinical Trials (2012) - Servier : Myocardial ischemia and heart failure. Perindopril, ivabradine, amlodipine, trimetazidine (2012) - Novartis : Acute heart failure. Saralaxine (2013-2014) - Boehringer-Ingelheim : Anticoagulants and diabetes. Dagabitran (2013-2014) - Medical Trials Analysis : Consultant in clinical trials - expertise (2013-2014) - Merk Serono : Coronary artery disease, heart failure, beta blockers (2013-2014) - Servier : Myocardial ischemia and heart failure. Perindopril, Ivabradine, Amlodipine, Trimetazidine (2013-2014) D - Research funding (departmental or institutional). - Fondazione Salvatore Maugeri : General (2012) - Schering-Plough : Anti-platelet agent TRACER (2012-2013-2014) |

Committee for Practice Guidelines 2012-2014

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts covering the period of the Guidelines production, from Task Force creation to publication.

| Expert | Type of Relationship with Industry |
|-----------------|---|
| Ferrari Roberto | <ul style="list-style-type: none"> - Servier : Perindopril, ivabradine, amlodipine CLARifY and SIGNifY (2012-2013-2014) |
| Hasdai David | <p>A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.</p> <ul style="list-style-type: none"> - Boehringer-Ingelheim : Pradaxa (2012-2013-2014) - Bayer : Rivaroxiban (2012-2013-2014) - Astra Zeneca : Ticagrelor (2012-2013-2014) |
| Hoes Arno | <p>B - Payment to your Institution: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.</p> <ul style="list-style-type: none"> - Boehringer-Ingelheim : Member Scientific Committee of Zorro; a research program sponsored by an unrestricted grant from Boehringer-Ingelheim with the aim to improve anticoagulant care in the Netherlands (2012) - Various : I chair a large (around 500 employees) research and teaching institute within our University Medical Center. We perform both investigator- and industry-driven research projects with a number of pharmaceutical and diagnostic companies. In addition, some of my members of staff receive unrestricted grants for research projects from a number of companies. It is our explicit policy to work with several companies and not to focus on one or two industrial partners. I receive no personal payment from any industrial partner. (2012-2013-2014) - Zorg binnen Bereik : Member of project team of Zorg Binnen Bereik, a Dutch Achmea (health insurance company) and Philips sponsored research program to test patient e-health platforms in patients with chronic disease (heart failure, COPD and diabetes) (2012-2013-2014) <p>D - Research funding (departmental or institutional).</p> <ul style="list-style-type: none"> - I am the director of a large (around 500 employees) research and teaching institute within our University Medical Center. We perform both investigator- and industry-driven research projects with a number of pharmaceutical and diagnostic companies. In addition, some of my members of staff receive unrestricted grants for research projects from a number of companies. It is our explicit policy to work with several companies and not to focus on one or two industrial partners. I receive no personal payment from any industrial partner. (2012-2013-2014) |
| Kirchhof Paulus | <p>A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.</p> <ul style="list-style-type: none"> - Boehringer-Ingelheim : cardiovascular (2012-2013-2014) - Daiichi Sankyo : cardiovascular (2012-2013-2014) - Medtronic : cardiovascular (2012-2013-2014) - Pfizer : cardiovascular (2012-2013-2014) - St Jude Medical : cardiovascular (2012-2013-2014) |

Committee for Practice Guidelines 2012-2014

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts covering the period of the Guidelines production, from Task Force creation to publication.

| Expert | Type of Relationship with Industry |
|-----------------|--|
| Kirchhof Paulus | <ul style="list-style-type: none"> - Sanofi Aventis : cardiovascular (2012-2013-2014) - Meda pharma : cardiovascular (2012-2013-2014) - Bristol Myers Squibb : cardiovascular (2012-2013-2014) - Merck Sharp & Dohme : cardiovascular (2012-2013-2014) - Otsuka Pharmaceuticals Development and Commercialization (consultancy) : cardiovascular (2012-2013-2014) - Johnson & Johnson : cardiovascular (2014) - Bayer Healthcare : cardiovascular (2014) <p>B - Payment to your Institution: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.</p> <ul style="list-style-type: none"> - Portola Pharmaceuticals : cardiovascular (2012) - Boehringer-Ingelheim : cardiovascular (2012-2013-2014) - Bayer Healthcare : cardiovascular (2012-2013-2014) - BMS / Pfizer alliance : cardiovascular (2012-2013-2014) - Gilead : cardiovascular (2013) - Daiichi Sankyo : cardiovascular (2014) <p>D - Research funding (departmental or institutional).</p> <ul style="list-style-type: none"> - St Jude Medical : cardiovascular (2012-2013) - Sanofi Aventis : cardiovascular (2012-2013) - Meda pharma : cardiovascular (2012-2013-2014) - British Heart Foundation : cardiovascular (2014) - European Union (FP7) : cardiovascular (2014) - Daiichi Sankyo : cardiovascular (IIT grant to AFNET) (2014) - St Jude Medical : cardiovascular (IIT grant to AFNET) (2014) - Sanofi Aventis : cardiovascular (IIT grant to AFNET) (2014) |

Committee for Practice Guidelines 2012-2014

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts covering the period of the Guidelines production, from Task Force creation to publication.

| Expert | Type of Relationship with Industry |
|----------------------|---|
| Kirchhof Paulus | <ul style="list-style-type: none"> - BMS/Pfizer : cardiovascular (IIT grant to AFNET) (2014) - Fondation Leducq : cardiovascular (starting in October 2014) (2014) - German Ministry of Education and Research (BMBF) : cardiovascular (to AFNET) (2014) |
| Knuuti Juhani | <p>A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.</p> <ul style="list-style-type: none"> - Lantheus Inc : Perfusion imaging tracer development (2012-2013-2014) <p>D - Research funding (departmental or institutional).</p> <ul style="list-style-type: none"> - Servier : Vascular inflammation (2012-2013-2014) - Athera : vascular inflammation (2012-2013-2014) - Orion Pharma : Heart failure drug research (2014) |
| Kolh Philippe H | <p>A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.</p> <ul style="list-style-type: none"> - Regado Biosciences : Antithrombotic agents (2012) - Astra Zeneca : Antiplatelet agents (2012-2013-2014) - B.Braun : Surgical instruments (2013-2014) <p>B - Payment to your Institution: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.</p> <ul style="list-style-type: none"> - Merck Sharp & Dohme : Antistaphylococcic vaccine (2012) <p>D - Research funding (departmental or institutional).</p> <ul style="list-style-type: none"> - St Jude Medical : Cardiac valves (2012-2013) - Boston Scientific : Coronary stents (2012-2013) - Siemens Healthcare : Medical imaging (2012-2013) - Johnson & Johnson : Thoracoscopic devices (2012-2013) - Edwards Lifesciences : Cardiac valves (2012-2013-2014) - Medtronic : Cardiac valves (2012-2013-2014) |
| Lancellotti Patrizio | <p>A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.</p> <ul style="list-style-type: none"> - Boston Scientific : Heart Failure (2012) - Servier : Heart Failure (2013) - Abbott : MitraClip (2013) |

Committee for Practice Guidelines 2012-2014

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts covering the period of the Guidelines production, from Task Force creation to publication.

| Expert | Type of Relationship with Industry |
|------------------------|--|
| Lancellotti Patrizio | <ul style="list-style-type: none"> - Menarini : nebivolol (2014) B - Payment to your Institution: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc. <ul style="list-style-type: none"> - Astra Zeneca : Brilique (2012) - Servier : Coversyl (2012) - Abbott Vascular : MitraClip (2012) - Astrazeneca : Dyslipidemia (2013) - Boston Scientific : CRT (2014) - Servier : procoralan (2014) D - Research funding (departmental or institutional). <ul style="list-style-type: none"> - Actelion : Pulmonary Hypertension (2013) |
| Linhart Ales | <ul style="list-style-type: none"> A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc. <ul style="list-style-type: none"> - Servier : Arterial hypertension (2012-2013-2014) - Boehringer-Ingelheim : Arterial hypertension, atrial fibrillation (2012-2013-2014) - GlaxoSmithKline : Atherosclerosis (2012-2013-2014) - Merck Sharp & Dohme : Dyslipidemia (2012-2013-2014) - Bayer Schering Pharma : Dyslipidemia, pulmonary hypertension, atrial fibrillation (2012-2013-2014) - Shire HGT : Fabry disease (2012-2013-2014) - Genzyme : Fabry disease (2012-2013-2014) - Actelion : Pulmonary hypertension (2012-2013-2014) B - Payment to your Institution: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc. <ul style="list-style-type: none"> - Shire HGT : Fabry disease (2012) D - Research funding (departmental or institutional). <ul style="list-style-type: none"> - Shire HGT : Fabry disease (2014) |
| Nihoyannopoulos Petros | <ul style="list-style-type: none"> None declared (2012) A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc. <ul style="list-style-type: none"> - GSK : Consultant for Imaging studies (2013-2014) |

Committee for Practice Guidelines 2012-2014

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts covering the period of the Guidelines production, from Task Force creation to publication.

| Expert | Type of Relationship with Industry |
|---------------------------|--|
| Piepoli Massimo Francesco | <p>None declared (2013-2014)</p> <p>A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc. - Chiesi Pharma : Anti-dyslipidemic therapy (2012)</p> |
| Ponikowski Piotr | <p>A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.</p> <ul style="list-style-type: none"> - Amgen : heart failure (2012) - Cothera : heart failure (2012) - Coridea : heart failure (2012) - Boehringer-Ingelheim : anticoagulant (2012-2013-2014) - Bristol Myers Squibb : anticoagulant (2012-2013-2014) - Respicardia : anticoagulant (2012-2013-2014) - Abbott Vascular : devices (2012-2013-2014) - Novartis : heart failure (2012-2013-2014) - Johnson & Johnson : heart failure (2012-2013-2014) - Bayer Healthcare : heart failure (2012-2013-2014) - Vifor Pharma ltd : heart failure (2012-2013-2014) - Pfizer : heart failure, anticoagulant (2012-2013-2014) - Servier : heart failure, coronary artery disease (2012-2013-2014) - Bayer : anticoagulant (2013-2014) - ROSCHE : diabetes (2013-2014) - Cardiorentis : heart failure (2013-2014) - CIBIEM : heart failure (2013-2014) - Amgen : heart failure, lipids (2013-2014) <p>D - Research funding (departmental or institutional). - Vifor Pharma ltd : heart failure (2012-2013-2014)</p> |

Committee for Practice Guidelines 2012-2014

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts covering the period of the Guidelines production, from Task Force creation to publication.

| Expert | Type of Relationship with Industry |
|-------------------|---|
| Sirnes Per Anton | <p>B - Payment to your Institution: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.</p> <ul style="list-style-type: none"> - Quintiles on behalf of Novartis : Investig fee CANTOS study (2012) - Merck Sharp & Dohme : Investigator fee HPS2-THRIVE STUDY (2012) - Boehringer-Ingelheim : Investigator Fee Reliable study (2012) - Schering-Plough : Investigator fee TRA2P-TIMI50 study (2012) - GlaxoSmithKline : Investig fee HZC113108 and LPL100601 studies (2012-2013) - SticaresInterACt on behalf of Servier : Investig Fee SIGNIFY study (2012-2013) - NORMA on behalf of Janssen Cilar : Invest fee CANVAS study (2012-2013-2014) - Amgen : Speeker fee (2013) - Pfizer : speeker fee (2013) - Quintiles on behalf Garfield AF Registry : Fee Garfield AF registry (2013-2014) - Novartis : Investigatoprs fee CANTOS study (2013-2014) |
| Tamargo Juan Luis | <p>A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.</p> <ul style="list-style-type: none"> - sanodi-aventis : Dronedarone-antiarrhythmic agent (2012) - Menarini : Ranolazina (2013) - Menarini : Ranolazine (2014) <p>B - Payment to your Institution: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.</p> <ul style="list-style-type: none"> - Astra Zeneca (Unrestricted Grant) : Candesartan, Felodipine, Atenolol (2014) <p>D - Research funding (departmental or institutional).</p> <ul style="list-style-type: none"> - Astra Zeneca : Unrestricted Grant (2013) <p>E - Research funding (personal).</p> <ul style="list-style-type: none"> - Astra -Zeneca Foundation (NON-PROFIT FOUNDATION). two years Unrestricted Grant : None (2012) - Instituto de Salud Carlos III. Ministerio de Economía y Competitividad. Gobierno de España : No product/device (2014) |
| Tendera Michal | <p>A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.</p> <ul style="list-style-type: none"> - Bayer : Aspirin, Rivaroxaban (2012) - Amgen : Darbopietin (2012) |

Committee for Practice Guidelines 2012-2014

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts covering the period of the Guidelines production, from Task Force creation to publication.

| Expert | Type of Relationship with Industry |
|----------------|---|
| Tendera Michal | <ul style="list-style-type: none"> - Servier : Ivabradine, Phase II investigational products (2012) - Amgen : Darbopoietine (2013) - Bayer : Aspirin, Acarbose (2013-2014) - Servier : Ivabradine (2013-2014) - Janssen Cilag : Rivaroxaban (2014) <p>B - Payment to your Institution: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.</p> <ul style="list-style-type: none"> - Servier : Ivabradine, Phase II investigational products (2012) - Servier : Ivabradine (2014) - Janssen-Cilag : Rivaroxaban (2014) |
| Torbicki Adam | <p>A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.</p> <ul style="list-style-type: none"> - Cardiomems : implanted pulmonary artery pressure sensor (2012) - United Therapeutics : Pulmonary arterial hypertension (2012) - Lilly : pulmonary arterial hypertension - tadalafil (2012) - AOP Orphan Pharmaceuticals : Pulmonary arterial hypertension - treprostinil (2012) - Bristol Myers Squibb : thromboembolic disease - Apixaban (2012) - GlaxoSmithKline : pulmonary arterial hypertension - ambrisentan (2012-2013) - Actelion : pulmonary arterial hypertension - macitentan, selexipag (2012-2013-2014) - Bayer Healthcare : pulmonary arterial hypertension - iloprost, riociguat, VTE - xarelto (2012-2013-2014) - Bristol Myers Squibb : Pulmonary arterial hypertension (2013) - Lilly : pulmonary arterial hypertension - ambrisentan (2013) - Novartis : pulmonary hypertension (2014) <p>B - Payment to your Institution: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.</p> <ul style="list-style-type: none"> - Sanofi Aventis : Thromboembolic disease (2012) - Bayer Healthcare : Pulmonary hypertension (2012-2013-2014) |

Committee for Practice Guidelines 2012-2014

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts covering the period of the Guidelines production, from Task Force creation to publication.

| Expert | Type of Relationship with Industry |
|---------------|--|
| Wijns William | <p>B - Payment to your Institution: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.</p> <ul style="list-style-type: none"> - Tryton : device (2012) - Astra Zeneca : pharma (2012) - Biosensors : device (2012-2013-2014) - Boston Scientific : device (2012-2013-2014) - Edwards Lifesciences : device (2012-2013-2014) - Medtronic : device (2012-2013-2014) - St Jude Medical : device (2012-2013-2014) - Biotronik : device (2012-2013-2014) - Terumo Inc : device (2012-2013-2014) - Abbott Vascular : device (2012-2013-2014) - Cordis : device (2012-2013-2014) - Orbus Nech : device (2012-2013-2014) - MICELL : device (2012-2013-2014) - Vessix : device (2012-2013-2014) - GlaxoSmithKline : drug (2012-2013-2014) <p>D - Research funding (departmental or institutional).</p> <ul style="list-style-type: none"> - Cardio3 Biosciences : cell therapy (2012-2013-2014) - Boston Scientific : device (2012-2013-2014) - Medtronic : device (2012-2013-2014) - St Jude Medical : device (2012-2013-2014) - Biotronik : device (2012-2013-2014) - Abbott Laboratories : device (2012-2013-2014) |

Committee for Practice Guidelines 2012-2014

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts covering the period of the Guidelines production, from Task Force creation to publication.

| Expert | Type of Relationship with Industry |
|--------------------------|--|
| Wijns William | <ul style="list-style-type: none"> - MICELL : device (2012-2013-2014) - Therabel : drug (2012-2013-2014) |
| Windecker Stephan | <p>A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.</p> <ul style="list-style-type: none"> - Biosensors : Stent (2012) - Boston Scientific : Stent (2012) - Cordis : Stent (2012) - Edwards Lifesciences : TAVI (2012) - Astra Zeneca : Antiplatelet drug (2012-2013) - Eli Lilly : Antiplatelet drug (2012-2013) - Abbott : Stent (2012-2013) - Medtronic : Stent (2012-2013) - Biotronik : Stent (2012-2013) <p>D - Research funding (departmental or institutional).</p> <ul style="list-style-type: none"> - Abbott : Stent (2012) - Biosensors : Stent (2012) - Medtronic : Stent (2012) - Cordis : Stent (2012) - St Jude Medical : OCT (2012-2013-2014) - Biotronik : Stent (2012-2013-2014) |
| Zamorano Gomez Jose Luis | <p>A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.</p> <ul style="list-style-type: none"> - Abbott Vascular : Help in Design Echocardiographic protocol (2012) - Merck Sharp & Dohme : Lecture (2012) - Daiichii : Atrial Fib (2013) - Merck Sharp & Dohme : Lipid Lowering (2013) |

Committee for Practice Guidelines 2012-2014

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts covering the period of the Guidelines production, from Task Force creation to publication.

| Expert | Type of Relationship with Industry |
|--------------------------|--|
| Zamorano Gomez Jose Luis | <ul style="list-style-type: none"> - Philips : 3D echo (2014) - MSD : CV risk factors (2014) - Toshiba medical imaging : fusion imaging 3D echo CT (2014) <p>B - Payment to your Institution: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.</p> <ul style="list-style-type: none"> - European Research Foundation FP7 : CV Imaging (2012) - European Research FP7 : CV Imaging (2013) - Servier : Imaging in ISchemic patients (2013) - Siemens Healthcare : 3d echo software and free style echo (2014) <p>C - Receipt of royalties for intellectual property.</p> <ul style="list-style-type: none"> - Springer : ESC Textbook of CV Imaging (2012-2013) <p>D - Research funding (departmental or institutional).</p> <ul style="list-style-type: none"> - Astra Zeneca : Clinical trial (2014) - Icaria : Clinical trial (2014) |